Ionis, Roche kidney disease drug meets main goal in mid-stage study

Nov. 07, 2022 7:30 AM ETIonis Pharmaceuticals, Inc. (IONS), RHHBY, RHHBFBy: Ravikash, SA News Editor2 Comments

Modern Medical Research Laboratory: Portrait of Latin and Black Young Scientists Using Microscope, Digital Tablet, Doing Sample Analysis, Talking. Diverse Team of Specialists work in Advanced Lab


  • Ionis Pharmaceuticals (NASDAQ:IONS) said a phase 2 trial of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN) met its main goal.
  • IgAN is a kidney disease which occurs when an antibody called immunoglobulin A (IgA) builds up in the kidneys causing inflammation.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.